LAWSUITS NEWS & LEGAL INFORMATION
Pfizer to Pay $141M Penalty For Neurontin Promotion
Boston, MA: A federal jury has concluded that Pfizer unlawfully promoted its epilepsy drug Neurontin, for off label use and must pay a $141 million penalty.
Kaiser Foundation Hospitals and Kaiser Foundation Health Plan, the plaintiffs in the lawsuit, alleged that Pfizer misled them into believing that Neurontin was effective as treatment for migraines and bipolar disorder. The U.S. Food and Drug Administration approved Neurontin to treat epilepsy in 1993.
The jury concluded that Pfizer had violated federal racketeering laws and imposed a penalty of $47 million, however that amount tripled under the federal Racketeer Influenced and Corrupt Organizations (RICO) Act.
Published on Mar-29-10
Kaiser Foundation Hospitals and Kaiser Foundation Health Plan, the plaintiffs in the lawsuit, alleged that Pfizer misled them into believing that Neurontin was effective as treatment for migraines and bipolar disorder. The U.S. Food and Drug Administration approved Neurontin to treat epilepsy in 1993.
The jury concluded that Pfizer had violated federal racketeering laws and imposed a penalty of $47 million, however that amount tripled under the federal Racketeer Influenced and Corrupt Organizations (RICO) Act.
Legal Help
If you have a similar problem and would like to be contacted by a lawyer at no cost or obligation, please click the link below.Published on Mar-29-10
READER COMMENTS
Melinda Nelson
on